Parabilis Medicines

Public

—N/Ahttps://parabilismed.com/

Last Round

Series F

Jan 8, 2026

Total Funding Raised

$801M

Company Overview

Parabilis Medicines is a clinical-stage biopharmaceutical company that develops stabilized helical peptide therapeutics, known as Helicons, to target undruggable protein-protein interactions in oncology.

AI Layer

Application

Keywords

peptide therapeuticsundruggable targetsAI drug discoveryWnt pathway inhibitorsβ-catenin inhibitorprotein-protein interaction inhibitorshelical peptidesPPI inhibitorsdrug discovery platformtargeted protein degradationprotein degradersclinical-stage biotechprecision oncologysolid tumor therapeuticsradioligand therapycolorectal cancer

Parabilis Medicines Comps

Public and private peers based on sector, stage, and business model.

Parabilis Medicines comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Parabilis Medicines Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series F	Jan 8, 2026
Series E	Mar 1, 2024
Series D	Nov 21, 2022
Series C	Mar 1, 2021
Series B	May 16, 2018

View all Funding Rounds

Key People

Founding team and executive leadership

Mathai Mammen

CEO, President And Chairman

Executive Team

Thomas Kotarakos

Chief Financial Officer

Executive Team

Parabilis Medicines Investors

Notable investors and investment history

Parabilis Medicines investors
Investor	Rounds
Soleus Capital	Series F
Janus Henderson Group	Series F
Horizons Ventures	Series B
Boyu Capital	Series B
RA Capital Management	Series E, Series F
Farallon Capital Management	Series F, Series C, Series E, Series D
Sixty Degree Capital	Series F, Series E

View all Investors

Parabilis Medicines Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Parabilis Medicines Filings

SEC and related filings with document metadata.

Firmographic Details

Headquarters—

Employee Range179

Year Founded2015

Last FundingJan 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.